Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Income: 2011-2025

Historic Net Income for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $36.4 million.

  • Adma Biologics' Net Income rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 207.41%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • Latest data reveals that Adma Biologics reported Net Income of $36.4 million as of Q3 2025, which was up 6.46% from $34.2 million recorded in Q2 2025.
  • Adma Biologics' 5-year Net Income high stood at $111.9 million for Q4 2024, and its period low was -$18.8 million during Q2 2021.
  • In the last 3 years, Adma Biologics' Net Income had a median value of $26.9 million in 2025 and averaged $24.3 million.
  • As far as peak fluctuations go, Adma Biologics' Net Income plummeted by 49.63% in 2023, and later surged by 1,299.96% in 2024.
  • Over the past 5 years, Adma Biologics' Net Income (Quarterly) stood at -$16.5 million in 2021, then climbed by 28.55% to -$11.8 million in 2022, then plummeted by 49.63% to -$17.6 million in 2023, then skyrocketed by 734.15% to $111.9 million in 2024, then rose by 1.45% to $36.4 million in 2025.
  • Its last three reported values are $36.4 million in Q3 2025, $34.2 million for Q2 2025, and $26.9 million during Q1 2025.